Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia

38Citations
Citations of this article
46Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

T cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of immature T lymphocytes, associated with higher rates of induction failure compared with those in B cell acute lymphoblastic leukemia. The potent immunotherapeutic approaches applied in B cell acute lymphoblastic leukemia, which have revolutionized the treatment paradigm, have proven more challenging in T-ALL, largely due to a lack of target antigens expressed on malignant but not healthy T cells. Unlike B cell depletion, T-cell aplasia is highly toxic. Here, we show that the chemokine receptor CCR9 is expressed in >70% of cases of T-ALL, including >85% of relapsed/refractory disease, and only on a small fraction (<5%) of normal T cells. Using cell line models and patient-derived xenografts, we found that chimeric antigen receptor (CAR) T-cells targeting CCR9 are resistant to fratricide and have potent antileukemic activity both in vitro and in vivo, even at low target antigen density. We propose that anti-CCR9 CAR-T cells could be a highly effective treatment strategy for T-ALL, avoiding T cell aplasia and the need for genome engineering that complicate other approaches.

Cite

CITATION STYLE

APA

Maciocia, P. M., Wawrzyniecka, P. A., Maciocia, N. C., Burley, A., Karpanasamy, T., Devereaux, S., … Mansour, M. R. (2022). Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia. Blood, 140(1), 25–37. https://doi.org/10.1182/blood.2021013648

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free